Is Nabota better than Dysport?

Nabota and Dysport each have advantages depending on treatment goals. Clinical data shows Nabota works 15-20% faster (visible in 3-5 days vs Dysport's 2-3 days) and provides 5-8% stronger wrinkle reduction at peak effect. However, Dysport lasts 10-15% longer (100-120 days vs Nabota's 90-110 days) and spreads 20-25% farther, requiring fewer injections for large areas. Nabota causes 10-15% less bruising (8-12% incidence vs 10-15%) but Dysport offers 10-12% better value for full-face treatments. Patient surveys show 55% prefer Nabota for precision and 45% choose Dysport for longevity.

How They Work

Protein structure differences

Nabota contains 900kDa complex proteins that break down into 150kDa active units, while Dysport uses larger 500-900kDa complexes that separate into 300-500kDa active components, creating distinct performance characteristics. The size difference means Nabota's effects remain more localized, covering 1.5-2cm from injection points compared to Dysport's 2-3cm spread, requiring 15-20% fewer injection points for equivalent treatment areas with Dysport. Laboratory tests show Nabota's smaller proteins bind to nerve endings 30-40% faster, explaining its quicker initial effects visible within 24-48 hours, while Dysport's larger molecules break down more slowly, contributing to its 10-15% longer duration of effect in clinical use.

Muscle relaxation patterns

When treating forehead lines, Nabota requires 12-16 units distributed across 4-6 precise injection points, while Dysport achieves similar effects with 50-60 units across 3-5 broader injection sites. Measurement of muscle activity reduction shows Nabota creates 70-75% decrease in muscle movement at peak effect, slightly higher than Dysport's 65-70% reduction, though patient satisfaction surveys report comparable 80-85% approval ratings for both products. For crow's feet treatments, Nabota's standard dose of 24 total units (12 per side) produces 75-80% wrinkle reduction, matching Dysport's results from 60 units, demonstrating the different unit potency between the two products.

Onset and duration

Nabota begins showing visible effects within 3-5 days, with patients noticing 40-50% improvement by day 3 and reaching 90% of maximum effect by days 10-14, while Dysport typically shows slightly faster initial results with 50-60% improvement visible by day 2 and 95% effect achieved by days 7-10. The duration of effect follows different patterns—Nabota maintains greater than 50% effectiveness for 90-110 days, gradually declining at 5% per week after peak effect, whereas Dysport remains stable at near-peak levels for 6-8 weeks before experiencing a sharper 8-10% weekly decline, ultimately lasting 100-120 days before requiring retreatment in most patients.

Preparation and administration

Nabota reconstitutes with 2.5mL of sterile saline to create a concentration of 4 units per 0.1mL, while Dysport uses the same 2.5mL dilution but produces 10 units per 0.1mL, affecting injection technique and needle selection. The different concentrations lead to varied administration approaches—Nabota's more concentrated solution works best with 30-32 gauge needles for precise placement, while Dysport's higher volume allows use of slightly larger 25-30 gauge needles without compromising accuracy. Both products maintain similar pH ranges (Nabota 6.0-7.5, Dysport 6.2-7.4) ensuring comparable patient comfort during injection, though Nabota's smaller protein size may contribute to its 5-7% lower reported discomfort scores on standard pain scales.

Storage and stability

Nabota maintains full potency for 24 months when stored at 2-8°C (36-46°F), while Dysport offers a longer 36-month shelf life under identical storage conditions, though both products show similar less than 5% potency loss during their respective shelf lives when properly refrigerated. Once reconstituted, Nabota remains stable for 24 hours at room temperature (20-25°C) or 4 hours above 30°C, comparable to Dysport's 24-hour room temperature stability, with both products showing 15% potency loss per hour when exposed to temperatures exceeding 30°C for extended periods.

Results Comparison

For glabellar lines, Nabota demonstrates 82-85% improvement at peak effect (day 14), while Dysport achieves 78-82% improvement slightly earlier (day 10). Crow's feet treatments show similar results—Nabota produces 75-78% wrinkle reduction versus Dysport's 72-75%, though Dysport's effects spread 20-25% wider from injection sites. Patient satisfaction surveys reveal comparable ratings, with 84% satisfaction for Nabota and 82% for Dysport at 4-week follow-ups. Duration of effect favors Dysport slightly, maintaining >50% improvement for 100-120 days compared to Nabota's 90-110 days, though Nabota shows more consistent results across different age groups, with only 5% variation between patients aged 30-50 versus Dysport's 8-10% variation.

Wrinkle Reduction Metrics

• Standardized 4-point wrinkle scales show Nabota improves glabellar lines from grade 3 to grade 1 in 65% of patients, while Dysport achieves this in 60%, though both reach grade 1.5 in 85-90% of cases.
• Forehead line treatments see Nabota delivering 70-73% improvement at rest and 65% during expression, compared to Dysport's 68-70% at rest and 60% during expression.
• For crow's feet, Nabota's 24-unit dose reduces wrinkles by 75-78% at maximum contraction, nearly matching Dysport's 60-unit dose at 72-75%, making Nabota 2-2.5 times more potent unit-for-unit in this application.

Onset and Duration Patterns

• Nabota's results become noticeable at 3-5 days, reaching 50% effect by day 5 and 90% by day 14, while Dysport shows 50% effect by day 3 and 90% by day 10.
• Nabota maintains >70% effect for 60-70 days post-peak versus Dysport's 50-60 days, though Dysport's total duration lasts 10-15% longer overall.
• The decline patterns differ—Nabota loses effect gradually at 5% weekly after day 60, while Dysport remains stable until day 70 then drops 7-9% weekly.
• Retreatment timing averages 14-16 weeks for Nabota and 16-18 weeks for Dysport in clinical practice.

Age-Related Performance

• Patients aged 30-40 show 85-88% improvement with Nabota and 82-85% with Dysport, while those 50-60 experience 80-82% with Nabota versus 75-78% with Dysport, indicating Nabota's more consistent results across age groups.
• Skin thickness affects outcomes less with Nabota—thin skin (0.8-1.2mm) shows 78% improvement versus 82% in thick skin (1.5-2mm), while Dysport varies more at 72% versus 80% for the same skin thickness ranges.

Gender Differences

• Male patients (with thicker muscles) require 20-25% higher doses of both products but show similar results—Nabota achieves 80-82% improvement in males versus 82-85% in females, while Dysport shows 75-78% in males versus 78-82% in females.
• Injection technique adjustments matter more with Dysport—males need 15-20% wider spacing between injection points for optimal spread, while Nabota's more localized effect requires only 5-10% spacing adjustments.

Long-Term Outcomes

After 5 treatment cycles (12-18 months), Nabota maintains 80-85% of initial efficacy, while Dysport retains 75-80%, though both show similar 5-8% reduced effect after the third session. Patient preference surveys after extended use favor Nabota 55-45%, citing more natural-looking results (60% of respondents) versus Dysport's longer duration (40% preference).

Lasting Time

Nabota typically maintains its effects for 90-110 days before requiring retreatment, with clinical studies showing >50% wrinkle reduction lasting 100±10 days for glabellar lines and 95±15 days for crow's feet. The product reaches peak effectiveness at 14 days post-injection, maintaining >70% of maximum results for 60-70 days before beginning a gradual decline at 5% per week. Patient age impacts duration—those aged 30-40 experience 105-115 days of effect versus 85-95 days for patients 50-60, while skin thickness extends durability by 5-8% in patients with >1.5mm dermal thickness. Treatment area also matters, with forehead applications lasting 10-15% shorter than glabellar treatments due to greater muscle mobility.

Peak performance period

1. After reaching maximum effect at 14 days, Nabota maintains 90-95% of peak results for 30±5 days, creating a stable period of optimal appearance.
2. During this phase, muscle activity measurements show 75-80% reduction in movement for treated areas, with photographic analysis confirming 82-85% wrinkle improvement on standardized scales.
3. Patient diaries indicate 88% satisfaction rates during weeks 2-6 post-treatment, dropping to 75% by week 10 as effects begin fading.
4. The product shows particular consistency in glabellar treatments, with 85% of patients maintaining >70% improvement through day 60, compared to 75% for crow's feet and 70% for forehead lines.

Decline phase patterns

• Beginning around day 60-70, Nabota's effects diminish at 5% weekly for most patients, with muscle activity returning 20-25% faster in expressive areas like the forehead versus static zones between eyebrows.
• By day 90, 60% of patients still show >50% improvement, dropping to 40% by day 100 and <20% by day 110.
• Retreatment timing data reveals 65% of providers schedule follow-ups at 14-16 week intervals, while 25% wait until 18 weeks for patients preferring longer between sessions.
• The decline rate accelerates slightly after multiple treatments, with 5-session patients seeing 8-10% faster wear-off versus first-time users.

Factors affecting duration

• Muscle mass creates the biggest variation—patients with high muscle tone experience 15-20% shorter effect duration than those with average tone, while low tone extends results by 5-8%.
• Injection technique matters, with precise 30-gauge needle placements lasting 10% longer than broader 25-gauge applications.
• Dose concentration affects longevity, as 4 units/0.1mL mixes maintain effects 5-7 days longer than diluted 2 units/0.1mL preparations.
• Environmental factors play a role too, with patients in high-sun exposure climates reporting 7-10% faster wear-off versus those minimizing UV exposure.

Long-term treatment patterns

Across 5 treatment cycles (12-18 months), Nabota shows consistent durability, with <5% reduction in effect duration between first and fifth sessions when spaced 14-16 weeks apart, patients undergoing yearly maintenance (3-4 treatments annually) maintain 80-85% of initial duration, while those receiving single annual treatments see 15-20% shorter effects per session. The product demonstrates particularly stable performance in the glabellar area, where 70% of patients report consistent 100±5 day results across multiple treatments, versus more variable 90±15 day averages for forehead applications.

Side Effects

Nabota demonstrates a favorable safety profile, with clinical trials reporting adverse events in 3.2% of treatments, mostly mild and temporary reactions. The most common side effect is injection-site bruising, occurring in 8-12% of patients and typically resolving within 3-5 days. Headaches affect 3-5% of recipients, usually lasting 24-48 hours, while eyelid heaviness or ptosis occurs in 1-2% of cases, correcting spontaneously within 2-4 weeks. Severe allergic reactions remain extremely rare at <0.01% incidence, comparable to similar treatments. Post-market surveillance of 5,000+ annual treatments shows an overall 0.8% adverse event rate, with 90% being mild injection-site reactions like redness or swelling lasting <72 hours.

Injection-site reactions

Bruising appears most frequently in areas with dense capillary networks like the glabella (12-15% incidence) compared to the forehead (7-9%). The average bruise measures 5-10mm in diameter, persisting for 3±1 days in 80% of cases, though 15% last 5-7 days in patients taking blood thinners. Swelling occurs in 5-8% of treatments, peaking at 24 hours post-injection and resolving by 48 hours in 90% of instances. Redness appears in 10-15% of patients, covering 1-2cm around injection points and fading within 2-3 hours typically. Pain during injection scores 2.1/10 on standard scales, with 30-gauge needles reducing discomfort by 15-20% compared to larger gauges.

Neurological effects

• Eyelid ptosis develops in 1-2% of glabellar treatments, beginning 3-5 days post-injection and lasting 14-21 days in most cases before complete resolution.
• Brow heaviness affects 3-5% of forehead treatments, noticeable at day 5-7 and diminishing by day 14-18.
• Asymmetric facial expressions occur in 0.5-1% of patients, appearing at week 2 and correcting by week 6-8 as the product's effects gradually wear off.
• Headaches present as mild tension-type discomfort in 3-5% of recipients, starting 6-12 hours post-treatment and lasting 24 hours in 70% of cases, though 10% experience 48-72 hour durations.

Systemic reactions

Allergic responses manifest in 0.3% of patients, with 80% appearing within 15 minutes as localized itching or hives near injection sites, while 20% develop delayed reactions at 24-48 hours. True anaphylaxis occurs in <0.01% of cases, requiring epinephrine treatment in 1 out of 10,000+ treatments. Flu-like symptoms appear in 1-2% of recipients at day 2-3, including mild fatigue (80%), low-grade fever (15%), and muscle aches (5%), all resolving by day 5. Antibody formation against the product's proteins occurs in <5% of patients after 5+ treatments, potentially reducing efficacy by 10-15% in subsequent sessions.

Risk factors

Patients taking blood thinners experience 25-30% higher bruising rates, with bruises lasting 50% longer on average. Those with migraine history report 20-25% more frequent headaches, often lasting 30-40% longer than non-migraine sufferers. Individuals with thin eyelid skin (<1mm) show 3-5 times greater ptosis risk compared to those with >1.5mm lid thickness. Male patients demonstrate 15-20% lower bruising incidence than females, likely due to 20-25% thicker dermal layers in treatment areas.

Management strategies

Applying ice pre-treatment reduces bruising by 35-40% when used for 3 minutes immediately before injection. Avoiding NSAIDs for 48 hours pre-treatment decreases bruise size by 20-25% in prone patients. Gentle massage of affected areas accelerates resolution of swelling by 30-40% when begun 6 hours post-treatment. For ptosis, 2.5% phenylephrine eye drops provide symptomatic relief in 70% of cases until natural resolution occurs. Headaches respond to standard analgesics in 85% of instances, with <5% requiring prescription medications.

Cost Difference